CSL Limited Deal History & Licensing Activity
CSL Limited is a large biotech headquartered in Australia. Over the past three years, CSL Limited has been involved in 1 licensing and acquisition transaction, with a primary focus on Gene Therapy (2 deals). The company currently has 29 active clinical trials, primarily in Rare Disease.
Deals (12mo)
2
Active Trials
29
Top Modality
Gene Therapy
Focus Area
Rare Disease
CSL Limited Recent Deal Activity
Licensing, acquisition, and partnership transactions involving CSL Limited in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Hemgenix | CSL | Gene Therapy | Approved | license | Mar 2026 |
CSL Limited Pipeline Focus
Therapeutic areas and modalities where CSL Limited is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
CSL Limited Strategic Signals
Key indicators of CSL Limited's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
CSL Limited Clinical Pipeline
CSL Limited has 29 active clinical trials across 4 development phases.
5
Phase 4
10
Unknown
8
Phase 2
6
Phase 3
See How Your Asset Matches CSL Limited's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About CSL Limited Licensing & Deal Activity
CSL Limited is a large biotech company based in Australia that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, CSL Limited ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for CSL Limited include Rare Disease (11 deals and trials), Autoimmune (3 deals and trials), Rare Disease (2 deals and trials), and Cardiovascular (2 deals and trials). In terms of modality, CSL Limited has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for CSL Limited and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against CSL Limited's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.